Statin-associated muscle symptoms in the VITamin D and OmegA-3 TriaL (VITAL)

Pedro Engel Gonzalez, Mark A. Hlatky*, Jo Ann E. Manson, Julie E. Buring, I. Min Lee, Nancy R. Cook, Vadim Bubes, Neil J. Stone

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

1 Scopus citations


Statins are highly effective medications that reduce risk of atherosclerotic cardiovascular disease, but are very commonly discontinued by patients because of muscle symptoms. The risk factors for statin-associated muscle symptoms (SAMS) are not well understood, so in this study we examined the predictors of SAMS in a well-studied cohort of patients in the VITAL trial. We found that female sex and younger age (50-64 years) were significant, independent predictors of higher rates of SAMS.

Original languageEnglish (US)
Pages (from-to)39-41
Number of pages3
JournalAmerican heart journal
StatePublished - Oct 2022

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Statin-associated muscle symptoms in the VITamin D and OmegA-3 TriaL (VITAL)'. Together they form a unique fingerprint.

Cite this